MX2012008635A - Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos. - Google Patents
Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos.Info
- Publication number
- MX2012008635A MX2012008635A MX2012008635A MX2012008635A MX2012008635A MX 2012008635 A MX2012008635 A MX 2012008635A MX 2012008635 A MX2012008635 A MX 2012008635A MX 2012008635 A MX2012008635 A MX 2012008635A MX 2012008635 A MX2012008635 A MX 2012008635A
- Authority
- MX
- Mexico
- Prior art keywords
- heteroaroylamino
- pharmaceuticals
- substituted
- oxygen
- propionic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula I, (Ver Formula), en la que A, D, E, G, R10, R30, R40, R50 y R60 tienen los significados indicados en las reivindicaciones, que son compuestos farmacéuticos activos valiosos. Son inhibidores de la proteasa catepsina A, y son útiles, por ejemplo, para el tratamiento de enfermedades tales como aterosclerosis, insuficiencia cardiaca, enfermedades renales, enfermedades hepáticas o enfermedades inflamatorias. La invención se refiere además a procedimientos para preparar los compuestos de la fórmula I, a su uso y a composiciones farmacéuticas que los comprenden.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305080 | 2010-01-26 | ||
US30911910P | 2010-03-01 | 2010-03-01 | |
PCT/EP2011/051038 WO2011092187A1 (en) | 2010-01-26 | 2011-01-26 | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012008635A true MX2012008635A (es) | 2012-08-23 |
Family
ID=42035666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008635A MX2012008635A (es) | 2010-01-26 | 2011-01-26 | Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos. |
Country Status (30)
Country | Link |
---|---|
US (2) | US8664257B2 (es) |
EP (2) | EP2826772A1 (es) |
JP (1) | JP5736390B2 (es) |
KR (1) | KR101764608B1 (es) |
CN (1) | CN102884052B (es) |
AR (1) | AR079967A1 (es) |
AU (1) | AU2011209333B2 (es) |
BR (1) | BR112012018253A2 (es) |
CA (1) | CA2784571A1 (es) |
CL (1) | CL2012002069A1 (es) |
CO (1) | CO6660462A2 (es) |
DK (1) | DK2528902T3 (es) |
ES (1) | ES2530073T3 (es) |
HK (1) | HK1178538A1 (es) |
HR (1) | HRP20150075T1 (es) |
IL (1) | IL220998A0 (es) |
MA (1) | MA33948B1 (es) |
MX (1) | MX2012008635A (es) |
MY (1) | MY156569A (es) |
NZ (1) | NZ601307A (es) |
PL (1) | PL2528902T3 (es) |
PT (1) | PT2528902E (es) |
RS (1) | RS53789B1 (es) |
RU (1) | RU2561126C2 (es) |
SG (1) | SG182659A1 (es) |
SI (1) | SI2528902T1 (es) |
TW (1) | TWI532725B (es) |
UY (1) | UY33200A (es) |
WO (1) | WO2011092187A1 (es) |
ZA (1) | ZA201204414B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102482249B (zh) | 2009-07-08 | 2016-06-08 | 德米拉(加拿大)公司 | 用于治疗皮肤病症或疾病状态的tofa类似物 |
EP2714660B1 (en) | 2011-05-31 | 2018-09-26 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
US8686184B2 (en) | 2011-05-31 | 2014-04-01 | Theravance, Inc. | Neprilysin inhibitors |
EP2714662B1 (en) | 2011-05-31 | 2017-10-11 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
RU2014107000A (ru) | 2011-07-26 | 2015-09-10 | Санофи | Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств |
BR112014001587A2 (pt) * | 2011-07-26 | 2017-02-14 | Sanofi Sa | derivados de ácido 3-(tiazol-4-carbonil)- ou 3-(tiazol-2-carbonil) amino-propiônico substituídos e seu uso como produtos farmacêuticos |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
EP2978754B1 (en) * | 2013-03-28 | 2017-05-10 | Sanofi | Biaryl-propionic acid derivatives and their use as pharmaceuticals |
KR20150136508A (ko) * | 2013-03-28 | 2015-12-07 | 사노피 | 바이아릴-프로피온산 유도체 및 약제로서의 그의 용도 |
US20160264536A1 (en) | 2013-10-23 | 2016-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
BR112018015191B1 (pt) | 2016-02-23 | 2023-10-17 | Pfizer Inc | Compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida, seu uso e composição farmacêutica que os compreende |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE226883C (de) | 1908-12-03 | 1910-10-11 | Draegerwerk Ag | UEberdruckoperationsapparat, bei welchem der Lunge des Patienten durch Mund und Nase die Atmungsluft unter moeglichst gleichbleibenden, geringem UEberdruck zugefuehrt wird |
DD226883A1 (de) | 1984-07-30 | 1985-09-04 | Neubauer T Paedagog Hochschule | Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen |
US5258397A (en) | 1988-11-30 | 1993-11-02 | Novapharme | 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions |
ATE164579T1 (de) | 1993-05-27 | 1998-04-15 | Shell Int Research | Herbizide thiazole-derivate |
JP2000169453A (ja) | 1998-09-30 | 2000-06-20 | Mitsubishi Chemicals Corp | 1―フェニルピラゾ―ル―3―カルボキサミド誘導体、その中間体およびこれを有効成分とする農薬 |
US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
US20040072802A1 (en) | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
EP1581523B1 (en) | 2002-12-23 | 2009-09-30 | Sanofi-Aventis Deutschland GmbH | Pyrazole-derivatives as factor xa inhibitors |
JP2005145839A (ja) | 2003-11-12 | 2005-06-09 | Japan Science & Technology Agency | 新規なカテプシンa阻害剤 |
ES2697524T3 (es) * | 2004-07-30 | 2019-01-24 | Exelixis Inc | Derivados de pirrol como agentes farmacéuticos |
CA2593156C (en) | 2005-01-10 | 2015-05-05 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
US20090209522A1 (en) | 2005-06-28 | 2009-08-20 | Graham Andrew Showell | Heterocyclic Non-Peptide GNRH Antagonists |
CN101104602A (zh) * | 2006-07-12 | 2008-01-16 | 赛诺菲-安万特 | N-[(1,5-二苯基-1h-吡唑-3-基)甲基]磺酰胺衍生物其制备、用途 |
FR2908409B1 (fr) * | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
WO2008139941A1 (en) | 2007-04-27 | 2008-11-20 | Takeda Pharmaceutical Company Limited | Substituted imidazole compound and use thereof |
EP2231615A1 (en) * | 2007-12-10 | 2010-09-29 | 7TM Pharma A/S | Cannabinoid receptor modulators |
EP2238128B1 (en) * | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
JP5560202B2 (ja) | 2007-12-26 | 2014-07-23 | サノフイ | P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体 |
ATE555107T1 (de) | 2008-02-21 | 2012-05-15 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo-ä2,2,1-üheptan-derivate |
EP2594557B1 (en) | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
-
2011
- 2011-01-24 TW TW100102413A patent/TWI532725B/zh not_active IP Right Cessation
- 2011-01-24 AR ARP110100220A patent/AR079967A1/es unknown
- 2011-01-24 UY UY0001033200A patent/UY33200A/es not_active Application Discontinuation
- 2011-01-26 RU RU2012136473/04A patent/RU2561126C2/ru not_active IP Right Cessation
- 2011-01-26 BR BR112012018253A patent/BR112012018253A2/pt not_active IP Right Cessation
- 2011-01-26 RS RS20150053A patent/RS53789B1/en unknown
- 2011-01-26 MA MA35095A patent/MA33948B1/fr unknown
- 2011-01-26 WO PCT/EP2011/051038 patent/WO2011092187A1/en active Application Filing
- 2011-01-26 DK DK11701123.9T patent/DK2528902T3/en active
- 2011-01-26 EP EP20140187399 patent/EP2826772A1/en not_active Withdrawn
- 2011-01-26 SG SG2012054185A patent/SG182659A1/en unknown
- 2011-01-26 AU AU2011209333A patent/AU2011209333B2/en not_active Ceased
- 2011-01-26 JP JP2012550422A patent/JP5736390B2/ja not_active Expired - Fee Related
- 2011-01-26 CA CA2784571A patent/CA2784571A1/en not_active Abandoned
- 2011-01-26 PL PL11701123T patent/PL2528902T3/pl unknown
- 2011-01-26 EP EP11701123.9A patent/EP2528902B1/en not_active Not-in-force
- 2011-01-26 MY MYPI2012002853A patent/MY156569A/en unknown
- 2011-01-26 CN CN201180016053.7A patent/CN102884052B/zh not_active Expired - Fee Related
- 2011-01-26 NZ NZ601307A patent/NZ601307A/en not_active IP Right Cessation
- 2011-01-26 KR KR1020127022317A patent/KR101764608B1/ko active IP Right Grant
- 2011-01-26 PT PT117011239T patent/PT2528902E/pt unknown
- 2011-01-26 ES ES11701123.9T patent/ES2530073T3/es active Active
- 2011-01-26 US US13/575,008 patent/US8664257B2/en not_active Expired - Fee Related
- 2011-01-26 SI SI201130368T patent/SI2528902T1/sl unknown
- 2011-01-26 MX MX2012008635A patent/MX2012008635A/es active IP Right Grant
-
2012
- 2012-06-15 ZA ZA2012/04414A patent/ZA201204414B/en unknown
- 2012-07-17 IL IL220998A patent/IL220998A0/en not_active IP Right Cessation
- 2012-07-25 CL CL2012002069A patent/CL2012002069A1/es unknown
- 2012-07-25 CO CO12124759A patent/CO6660462A2/es active IP Right Grant
-
2013
- 2013-05-28 HK HK13106299.0A patent/HK1178538A1/xx not_active IP Right Cessation
-
2014
- 2014-01-10 US US14/151,951 patent/US20140128616A1/en not_active Abandoned
-
2015
- 2015-01-20 HR HRP20150075AT patent/HRP20150075T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY156569A (en) | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
MX337173B (es) | Derivados de acido 3-heteroaroilamino-propionico y sus usos como productos farmeceuticos. | |
MX340370B (es) | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas. | |
MY162786A (en) | Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals | |
MY161165A (en) | Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
MY165087A (en) | Neprilysin inhibitors | |
MX354476B (es) | Inhibidores de neprilisina. | |
MY170935A (en) | Neprilysin inhibitors | |
MX342212B (es) | Inhibidores de neprilisina. | |
UA111770C2 (uk) | Інгібітори бромдомену | |
GEP20146197B (en) | New compounds | |
PH12015500260A1 (en) | Neprilysin inhibitors | |
WO2011127290A3 (en) | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | |
TR201902788T4 (tr) | Nörodejeneratif hastalıkların tedavisinde kullanışlı 1-arilkarbonil-4-oksi-piperidin bileşikleri. | |
MD20140124A2 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
MY157423A (en) | Production method of intermediate compound for synthesizing medicament | |
WO2011047055A8 (en) | Novel mek inhibitors, useful in the treatment of diseases | |
UA116877C2 (uk) | Сполука з антибактеріальною і/абопротивірусною активністю | |
MX2015013799A (es) | Derivados de acido-biaril-propionico y su uso como productos farmaceuticos. | |
MX2015013800A (es) | Derivados de acido-biaril-propionico y su uso como productos farmaceuticos. | |
CY1116085T1 (el) | Παραγωγα οξυγονο- υποκατεστημενου 3-ετεροαροϋλαμινο- προπιονικου οξεος και η χρηση τους ως φαρμακευτικες ουσιες |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |